Investor Presentaiton slide image

Investor Presentaiton

Cell therapy: CAR-T is by far the Most Popular Modality Currently Focused on Hematological Malignancies, Solid Tumor Targets and Autoimmune Disease Targets are also being Pursued Cell therapy pipeline breakdown by cell type and phase BLA/ approval 1,200 Ph3 Ph2/3 1,000 Ph2 Ph1/2 800 Ph1 Modified T cells Unmodified T cells NK cells 600 IND 400 PCC 200 0 Source: Pharm Cube NextPharma database; Date cutoff 05/2023 CAR-T TCR-T CAR-VOT CAR-Treg CAR-CIK TCR-YOT TIL Treg убт CIK Others CAR-NK NK Macrophages TCR-NK CAR-M Macrophage Dendritic cells Pipeline breakdown by target 0% 2% 4% 6% 8% CD19 BCMA CD22 CD20 CD33 CD123 DC Hematological malignancies CD7 CLL-1 CD38 MSLN HER2 GPC3 EGFR NY-ESO-1 CLDN18.2 CD70 Solid tumour B7-H3 EBV KARS PSMA 3 药明康德 Wuxi AppTec
View entire presentation